A Study of Belimumab in Treating Symptomatic Waldenstroms Macroglobulinaemia
Status:
Unknown status
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
Hypothesis; That inhibition of plasma Blys by the monoclonal antibody Belimumab will reduce
both the survival of the lymphoplasmacytoid cells of Waldenstrom Macroglobulinaemia (WM), and
their production of monoclonal IgM, resulting in a reduction of IgM paraprotein.